Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Kobayashi, Kazuo; Toyoda, Masao; Hatori, Nobuo; Sakai, Hiroyuki; Furuki, Takayuki; Chin, Keiichi; Kimura, Moritugu; Saito, Nobumichi; Kanaoka, Tomohiko; Aoyama, Togo; Umezono, Tomoya; Ito, Shun; Suzuki, Daisuke; Takeda, Hiroshi; Minagawa, Fuyuki; Degawa, Hisakazu; Machimura, Hideo; Hishiki, Toshimasa; Umezawa, Shinichi; Shimura, Hidetoshi; Nakajima, Sachiko; Yamamoto, Hareaki; Sato, Kazuyoshi; Miyakawa, Masaaki; Terauchi, Yasuo; Tamura, Kouichi; Kanamori, Akira

doi:10.1016/j.diabres.2022.109231

Cited by 8 publications

(20 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are similar to those of our previous study (25). There was no signi cant difference in the decrease in LnACR between the two groups.…”

Section: Discussionsupporting

confidence: 92%

“…In turn, GLP-1Ras' renoprotective effects may be a consequence of increased sodium excretion due to the inhibition of the sodium-hydrogen exchanger isoform 3 (41) or anti-in ammatory and antioxidant effects (42,43). In our previous studies, we found that SGLT-2i treatment is associated with a larger decrease in BP than GLP-1Ra treatment, and that this effect is strongly correlated with their renoprotective effects (25). Regarding the secondary outcome, we selected the ATE weighting model associated with PS-based trimming for generating minimal standardized differences.…”

Section: Discussionmentioning

confidence: 86%

“…T2DM patients and that, in SGLT2i-treated patients, the decrease in BP is signi cantly correlated with the decrease in ACR (P = 0.04) (25).…”

mentioning

confidence: 85%

“…This study is a sub-analysis of our previous study and the methods of this study was already described in our previous report (25). In short, the Kanagawa Physicians Association carried out two retrospective surveys that included patients with T2DM receiving SGLT-2i or GLP-1Ra therapy to investigate their in uence on renal function.…”

Section: Study Patients and Data Collectionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of the blood pressure management between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Kobayashi

Toyoda

Hatori

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Reduction in blood pressure (BP) contributes to the cardiovascular and renal protective effects of sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP-1Ras). However, there has been no direct comparison in terms of BP-lowering efficacies. We compared the rates of achieving a target BP with SGLT-2i and GLP-1Ra treatments administered to Japanese patients with type 2 diabetes mellitus (T2DM). This retrospective study included 384 SGLT-2i- and 160 GLP-1Ra-treated patients with a BP > 130/80 mmHg before treatment. Inverse probability weighting methods using propensity scores were applied in this study. The integrated odds ratios (OR) for BP control rates were calculated and clinical changes were analyzed using a generalized linear model. SGLT-2i treatment resulted in significantly higher BP control rates than the GLP1Ra treatment (integrated OR = 2.09 [1.80, 2.43]). Compared with GLP-1Ra, SGLT-2i treatment determined significantly larger decreases in diastolic BP, mean arterial pressure, and body weight (-3.8 mmHg, P = 0.006; -4.1 mmHg, P = 0.01; and -1.5 kg, P = 0.008, respectively) and increased annual estimated glomerular filtration rate (eGFR; 1.5 mL/min/1.73 m2/year, P = 0.04). In T2DM patients with poorly controlled BP, compared with GLP-1Ra, SGLT-2i treatment significantly improved BP management along with increasing eGFR.

show abstract

“…These results are similar to those of our previous study (25). There was no signi cant difference in the decrease in LnACR between the two groups.…”

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 86%

“…T2DM patients and that, in SGLT2i-treated patients, the decrease in BP is signi cantly correlated with the decrease in ACR (P = 0.04) (25).…”

mentioning

confidence: 85%

Section: Study Patients and Data Collectionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of the blood pressure management between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Kobayashi

Toyoda

Hatori

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, there was a propensity-score matched retrospective cohort analysis of detailed kidney outcomes among patients with type 2 diabetes in Japan treated with SGLT2i ( n = 541) and GLP1RA ( n = 265) respectively, 28 which was the first in the literature to compare both agents head-to-head for kidney outcomes directly. The definitions of kidney outcomes were different from CVOTs – defined as annual eGFR decline by >15% and/or worsening in UACR category.…”

Section: Discussionmentioning

confidence: 99%

Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis

Lui

Tang

et al. 2022

eClinicalMedicine

View full text Add to dashboard Cite

No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study

Bodini,

Pieralice,

D'Onofrio

et al. 2024

Clinical Therapeutics

View full text Add to dashboard Cite

Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Cited by 8 publications

References 47 publications

Comparison of the blood pressure management between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Comparison of the blood pressure management between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists

Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis

No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study

Contact Info

Product

Resources

About